secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pluri Inc. (PLUR)
CIK:        0001158780
Form:       8-K
Filed at:   2022-07-13T23:59:59+00:00
Accession:  0001213900-22-039009
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Pluristem Phase III hip fracture study misses primary endpoint but meets key secondary muscle strength measure
--------------------------------------------------------------------------------

- Primary endpoint SPPB at week 26 not met; PLX-PAD showed no significant improvement vs placebo.
- Hip Abduction Strength (HAS) significantly improved: injured leg +2kg at wk26 (p=0.047) and +4kg at wk52 (p=0.0022).
- Uninjured leg also benefited: +1.8kg at wk26 (p=0.073) and +4kg at wk52 (p=0.0046) vs placebo.
- 6-minute walk test at wk52: PLX-PAD patients walked 296m vs 266m for placebo (positive trend).
- Company plans to seek regulatory advice and explore partnerships to advance PLX-PAD development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1158780/000121390022039009/0001213900-22-039009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1158780/000121390022039009/ea162806-8k_pluristem.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-039009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer